Cell Therapeutics, Inc. is continuing the clinical development of pixantrone by planning an additional Phase III trial with pixantrone in aggressive NHL. The trial will be an international, multicenter, randomized, active-controlled, single-blind (open label to patients and investigators only) study comparing the efficacy and safety of pixantrone treatment with that of a comparator arm.

If you would like more information about this trial, including sites in your area when it is available, please submit the following form to stay updated.